Oncologists must continue to ration the critical bladder cancer therapy bacillus Calmette-Guérin (BCG) among high-risk patients as the global shortage of the immunotherapy is set to continue well into 2021. The bacteria-based immunotherapy, which has been standard care for non muscular invasive bladder cancer for more than three decades, beats out both surgery and chemotherapy ...
‘Outrageous’: the best treatment for bladder cancer is out of production
By Sunalie Silva
13 Mar 2020